Feb. 3 at 9:42 PM
$AQST
Now that the major risk is gone, this is exactly where institutions usually step in.
Aquestive Therapeutics (AQST) is no longer a binary biotech bet.
It was packaging / human-factor fixes only.
For institutions, this changes everything.
Before → too risky, small positions
Now → de-risked, clearer path, easier to size up
This is typically when funds get more aggressive, not cautious.
They prefer:
• de-risked biotech
• clear resubmission path
• discounted valuation
AQST checks all three.
And let us be realistic — a 40% move in one day was not retail traders guessing.
We do not have insider info or “gut feelings” strong enough to create that kind of volume.
Moves like that usually come from serious money stepping in.
It feels like that spike was the beginning of institutional positioning, not the end of the run.
Now we are entering a different phase —
not speculation, but accumulation.
Not “if approved” anymore.
More like “when approved.”
